Dynamics of SARS-CoV-2 variants of concern (VOC) in Bangladesh during the first half of 2021
- PMID: 34700068
- PMCID: PMC8531988
- DOI: 10.1016/j.virol.2021.10.005
Dynamics of SARS-CoV-2 variants of concern (VOC) in Bangladesh during the first half of 2021
Abstract
Bangladesh is the second-worst-affected country in South Asia by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The aim of this study is to examine genome sequences from Bangladesh from January 2021 to June 2021 in order to monitor the SARS-CoV-2 VOC and the clades or lineages that are prevalent in the country. Within the study timeframe, at least eight Nextstrain clades were found: 20A, 20B, 20C, 20H (Beta, V2), 20I (Alpha, V1), 20 J (Gamma, V3), 21A (Delta), 21D (Eta), and six GISAID clades: four main (G, GH, GR, GRY) and two minors (GV, O) with an introduction of VOC B.1.1.7/Alpha, B.1.351/Beta and B.1.617.2/Delta. The introduction and recent occurrence of VOCs with substantial alterations in the receptor binding site of spike protein (K417 N, K417T, L452R, T478K, E484K, S494P, N501Y) are of particular importance. Specifically, VOC B.1.617.2/Delta has surpassed all prior VOCs in Bangladesh, posing a challenge to the existing disease management.
Keywords: Bangladesh; Mutation; Phylogeny; SARS-CoV-2; Sequence; Variant.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
The authors declare no potential conflict of interest.
Figures
References
-
- Afrin S.Z., Paul S.K., Begum J.A., Nasreen S.A., Ahmed S., Ahmad F.U., Aziz M.A., Parvin R., Aung M.S., Kobayashi N. Extensive genetic diversity with novel mutations in spike glycoprotein of severe acute respiratory syndrome coronavirus 2, Bangladesh in late 2020. New Microbes New Infect. 2020;41 doi: 10.1016/j.nmni.2021.100889. - DOI - PMC - PubMed
-
- Allen H., Vusirikala A., Flannagan J., Twohig K.A., Zaidi A., Consortium C.O.G.-U.K., Groves N., Lopez-Bernal J., Harris R., Charlett A., Dabrera G., Kall M. 2021. Increased Household Transmission of COVID-19 Cases Associated with SARS-CoV-2 Variant of Concern B. 1.617. 2: a National Case Control Study. Public Health England.http://efaidnbmnnnibpcajpcglclefindmkaj/viewer.html?pdfurl=https%3A%2F%2... chrome-extension.
-
- Collier D.A., De Marco A., Ferreira I., Meng B., Datir R., Walls A.C., Kemp S S.A., Bassi J., Pinto D., Fregni C.S., Bianchi S., Tortorici M.A., Bowen J., Culap K., Jaconi S., Cameroni E., Snell G., Pizzuto M.S., Pellanda A.F., Garzoni C., Gupta R.K. 2021. SARS-CoV-2 B.1.1.7 Sensitivity to mRNA Vaccine-Elicited, Convalescent and Monoclonal Antibodies. medRxiv: the Preprint Server for Health Sciences. - DOI
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
